ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: The end of the search or a need for further investigations?

American Journal of Hypertension

Volumn 15, Issue 4 I, 2002, Pages 367-371

  Ruilope, Luis M ^a   Coca, Antonio ^a,b   Volpe, Massimo ^c   Waeber, Bernard ^d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

ACE inhibition; Antihypertensive therapy; Arterial hypertension; Trials

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PERINDOPRIL; VASOPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HUMANS; HYPERTENSION; MORBIDITY; RESEARCH DESIGN;

EID: 0036117515     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(02)02258-6     Document Type: Note

References (47)

1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
2. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
3. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure. Overview of randomised drug trials in their epidemiological context
4. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
5. The effects of antihypertensive treatment on vascular disease: Reappraisal of the evidence
6. Combination therapy under investigation in large-scale trials: The INVEST study
7. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Lessons I-VI
8. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Lessons VII-IX
9. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Lessons X-XII
10. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
11. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats
12. Relation of plasma renin to and-organ damage and to protection of K+ feeding in stroke-prone hypertensive rats
13. DuP 753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet
14. Angiotensin converting enzyme inhibitors in hypertension
15. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
16. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies
17. Blood pressure control, proteinuria and renal outcome in chronic renal failure
18. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
19. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
20. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
21. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
22. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
23. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
24. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
25. The effect of angiotensin-converting enzyme therapy on diabetic nephropathy
26. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
27. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
28. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes
29. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes
30. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
31. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
32. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials
33. Mortalidad relacionada con la hipertensión y la presión arterial en España
34. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data
35. Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients
36. Case-control study of stroke and the quality of hypertension control in north west England
37. Cardiovascular protection and blood pressure reduction
38. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack
39. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
40. Randomized trial of effects of calcium antagonist compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension. The NORdic DILtiazem (NORDIL) Study
41. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
42. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
43. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
44. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
45. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes